Zoom In on Dementia & Alzheimer's

Explore Bio-Hermes-002, an innovative study investigating how blood and digital biomarkers can predict the likelihood of Alzheimer’s pathology. This research aims to identify more accessible methods for Alzheimer’s detection and determining treatment eligibility. If you’re between 60-90 years old and have a study partner, join us to learn how you can get involved.

This episode is designed to demystify the emerging field of blood-based biomarkers in Alzheimer’s disease. Join us to learn the basics of what blood biomarkers are, how they work, and why they’re considered a game-changer in Alzheimer’s research and clinical care. 

Advancements in diagnostic technologies such as blood tests and AI-based models is making early detection of dementia quicker, less expensive, more accurate and more accessible than ever before. Join Dr. David M. Holtzman, a leading neurologist and Alzheimer’s expert as he shares insights on the latest diagnostic methods, when and how to seek a diagnosis, and how to navigate the process.

The Synaptic Therapy Alzheimer’s Research Trial (START) study, currently enrolling participants at sites across the U.S., is evaluating a new oral capsule designed to slow memory loss in Alzheimer’s by safeguarding synapses in the brain. Join lead research scientist Dr. Christopher van Dyck to learn more.

From the underlying genetics to emerging treatments options, scientists are rapidly gaining knowledge about the detection, diagnosis and treatment of FTD. For the latest information, and to learn about participating in clinical trials for FTD please join our discussion with Dr. Brad Dickerson.

Join Cognito Therapeutics CEO, Brent Vaughan to talk about the pivotal HOPE Study, currently open for recruitment, which uses an investigational medical device consisting of headphones and eyewear to deliver sensory stimulation treatment in the comfort of people’s homes. The HOPE Study explores if this approach will potentially prove to slow the progression of mild to moderate Alzheimer’s disease.

On July 2, 2024, the U.S. Food and Drug Administration approved Kisunla (donanemab), a new Alzheimer’s medication shown to slow the progression of the disease. Join our conversation with Dr. Paul Aisen as he details how the drug works, for whom, side effects, what it costs, whether it’s covered by insurance, and how it compares with other new Alzheimer’s medicines.

If you learn about your specific genetic makeup early enough – before symptoms of memory loss begin – could you benefit from this knowledge? Join us as we explore the importance of understanding your genetic risk for Alzheimer’s and related dementias.

Are you between 18-95 years old and interested in brain health? Learn from leading scientists about two research opportunities that do NOT involve taking medications: the Emory Healthy Aging Study and the NeuroQuest Study.

Are AI programs the next frontier in forecasting, understanding, and managing Alzheimer’s? Dr. Timothy Hohman gives us the scoop on all things AI and dementia.

Distinguished Alzheimer’s expert Dr. Gil Rabinovici explains how early-onset Alzheimer’s is recognized, diagnosed, and treated and what separates it from the most common form of the disease.

An international brain health expert helps to decipher the best evidence-based lifestyle strategies for protecting your brain as you age.

Listen to world-renowned Alzheimer’s expert Dr. Marwan Sabbagh as he guides us through the complex stages and progression of Alzheimer’s and helps us understand the resources available at each stage.

In 2023, there were 184 trials assessing 143 drugs for the treatment of Alzheimer's disease (AD) and Mild Cognitive Impairment, with more than 60,000 participants required to populate those registered trials at 5684 sites. What is happening in 2024? Find out with Dr. Jeffrey Cummings for the insider’s overview.

Three new drugs for Alzheimer’s disease have been approved, and pharmaceutical companies are currently testing 141 Alzheimer’s drugs in 178 clinical trials. World-renowned expert Dr. Reisa Sperling discusses what might be coming through the treatment pipeline for dementias within the next three years.

There is no wonder drug or miracle cure for Alzheimer’s and related dementias, but research studies show that lifestyle choices can cut down your risk. Join Dr. Richard S. Isaacson as he shares insights on how preventative lifestyle changes and individualized care can meaningfully reduce your dementia risk and benefit your overall health.